Background: Preoperative prediction of prolonged postoperative opioid use (PPOU) after total knee arthroplasty (TKA) could identify high-risk patients for increased surveillance. The Skeletal Oncology Research Group machine learning algorithm (SORG-MLA) has been tested internally while lacking external support to assess its generalizability. The aims of this study were to externally validate this algorithm in an Asian cohort and to identify other potential independent factors for PPOU.Methods: In a tertiary center in Taiwan, 3,495 patients receiving TKA from 2010–2018 were included. Baseline characteristics were compared between the external validation cohort and the original developmental cohorts. Discrimination (area under receiver operating characteristic curve [AUROC] and precision-recall curve [AUPRC]), calibration, overall performance (Brier score), and decision curve analysis (DCA) were applied to assess the model performance. A multivariable logistic regression was used to evaluate other potential prognostic factors.Results: There were notable differences in baseline characteristics between the validation and the development cohort. Despite these variations, the SORG-MLA (https://sorg-apps.shinyapps.io/tjaopioid/) remained its good discriminatory ability (AUROC, 0.75; AUPRC, 0.34) and good overall performance (Brier score, 0.029; null model Brier score, 0.032). The algorithm could bring clinical benefit in DCA while somewhat overestimating the probability of prolonged opioid use. Preoperative acetaminophen use was an independent factor to predict PPOU (odds ratio, 2.05).Conclusions: The SORG-MLA retained its discriminatory ability and good overall performance despite the different pharmaceutical regulations. The algorithm could be used to identify high-risk patients and tailor personalized prevention policy.
13 July 2023 in Journal of the Formosan Medical Association
Identifying patients at risk of prolonged opioid use after surgery prompts appropriate prescription and personalized treatment plans. The Skeletal Oncology Research Group machine learning algorithm (SORG-MLA) was developed to predict the risk of prolonged opioid use in opioid-naive patients after lumbar spine surgery. However, its utility in a distinct country remains unknown. A Taiwanese cohort containing 2795 patients who were 20 years or older undergoing primary surgery for lumbar decompression from 2010 to 2018 were used to validate the SORG-MLA. Discrimination (area under receiver operating characteristic curve [AUROC] and area under precision-recall curve [AUPRC]), calibration, overall performance (Brier score), and decision curve analysis were applied. Among 2795 patients, the prolonged opioid prescription rate was 5.2%. The validation cohort were older, more inpatient disposition, and more common pharmaceutical history of NSAIDs. Despite the differences, the SORG-MLA provided a good discriminative ability (AUROC of 0.71 and AURPC of 0.36), a good overall performance (Brier score of 0.044 compared to that of 0.039 in the developmental cohort). However, the probability of prolonged opioid prescription tended to be overestimated (calibration intercept of -0.07 and calibration slope of 1.45). Decision curve analysis suggested greater clinical net benefit in a wide range of clinical scenarios. The SORG-MLA retained good discriminative abilities and overall performances in a geologically and medicolegally different region. It was suitable for predicting patients in risk of prolonged postoperative opioid use in Taiwan.
26 July 2025 in Journal of Orthopaedic Surgery and Research
The rising prevalence of metastatic bone disease (MBDex) of the extremities substantially affects patient quality of life due to skeletal-related events. Determining whether surgical intervention benefits patient survival is crucial in the management of MBDex. However, there is currently limited evidence regarding the survival impact of upper versus lower extremity involvement. This study aims to evaluate differences in survival outcomes regarding metastatic site, and the impact of operative versus nonoperative management. This retrospective cohort study evaluated 1,719 patients with a two-year follow-up period after treatment for MBDex at a major tertiary medical center in Taiwan from 2010 to 2018. Inclusion criteria included patients aged over 20 who underwent operative or nonoperative management. Exclusion criteria involved patients with concurrent upper and lower extremity metastases. Kaplan–Meier curves and multivariate Cox regression models were used to analyze survival and prognostic factors. Compared to upper MBDex, lower MBDex patients have poorer pretreatment Eastern Cooperative Oncology Group (ECOG) performance status. Lower MBDex was associated with worse two-year survival, particularly among those receiving nonoperative management. Common prognostic factors included ECOG performance status, Charlson’s comorbidities, primary tumor type, and albumin levels, while previous systemic treatment and the presence of visceral and brain metastases were specifically detrimental in lower MBDex. Lower MBDex is associated with poorer survival outcomes. Operative management is associated with survival benefit in lower MBDex, a benefit not as pronounced in upper MBDex. These findings highlight the importance of differentiating between upper and lower extremity metastases in survival analyses and prediction.
8 June 2024 in Journal of the Formosan Medical Association
Aims: Managing proximal humerus pathologic fractures requires strategic planning to ensure optimal patient outcomes. Traditionally, fixation of the humerus using long devices has been considered the standard of care, but emerging evidence has challenged this approach. This study aimed to compare long plates (LPs) and intermediate-length plates (IPs) in this clinical context. Methods: Forty-four patients with proximal humerus metastatic bone disease were retrospectively studied from 2013 to 2019, with 11 (25%) receiving long plates (LPs) and 33 (75%) intermediate-length plates (IPs). Outcomes included tumor progression, reoperation rates, postoperative anemia, blood loss, operation time, and hospitalization duration. Tumor progression was classified into three categories, with Type III progression (new metastatic lesions in the distal humerus) theoretically benefiting most from whole bone stabilization. Results: Tumor progression occurred in three patients (7%), all of them was in IPs. No revision surgery was needed to address these tumor progressions, including one type III progression which occurred 34 months postoperatively after IP surgery. IP were associated with a reduced operation time compared with LP (median, 1.5 h [IQR, 1.2–1.9] vs. 2.4 [IQR, 1.7–2.5]; p = 0.004). No differences were found for the other perioperative outcomes. Conclusions: Our findings reveal a low incidence of tumor progression and low reoperation rates in both groups. The shortened operative time associated with IP use suggests its particular suitability for patients with limited life expectancy. Further research is needed to elucidate the ideal prosthesis length that best balances the risks and benefits when addressing proximal humerus metastatic disease.
Background: Vascular endothelial growth factor inhibitors (VEGFi) are widely used for metastatic cancer management but are known to impair wound-healing. In spinal metastasis surgery, postoperative wound complications remain a clinical challenge, and the perioperative management of systemic antineoplastic therapies remains poorly defined. Current recommendations regarding postoperative VEGFi reinitiation are largely consensus-based and range from 28 to 40 days. The aims of this study were to evaluate the association between perioperative antineoplastic therapies and wound complications and to define the optimal timing of postoperative VEGFi reinitiation. Methods: This retrospective cohort study included 1,164 Taiwanese patients (684 male and 480 female; median age, 60.7 years [interquartile range, 51.5 to 68.8 years]) who underwent spinal metastasis surgery at a single tertiary center between 2010 and 2022. The outcome was postoperative wound complications within 90 days. Multivariable logistic regression was used to identify independent risk factors. The association between the timing of postoperative VEGFi reinitiation and wound complications was assessed using receiver operating characteristic curve analysis and the Fisher exact test. Results: Wound complications occurred in 301 patients (25.9%). Multivariable analysis identified diabetes mellitus (odds ratio [OR] = 4.58; p < 0.001), poor performance status (Eastern Cooperative Oncology Group score ≥2; OR = 3.07; p = 0.002), perioperative use of VEGFi (OR = 4.12; p < 0.001), and perioperative use of antimetabolites (OR = 2.24; p = 0.04) as independent risk factors. Patients reinitiating VEGFi within 40 days had higher complication rates than both nonusers and those reinitiating VEGFi after 40 days, with the former comparison reaching statistical significance. Conclusions: One-quarter of the patients undergoing spinal metastasis surgery experienced postoperative wound complications. Perioperative use of VEGFi was an independent predictor, and our results suggest that there should be a postoperative cessation interval of 40 days to reduce wound-related risk. Clinicians should balance the oncologic benefits of early VEGFi reinitiation against the heightened risk of complications. Level of Evidence: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
20 October 2026 in Journal of the Formosan Medical Association